Literature DB >> 22537806

Lyophilization of cholesterol-free PEGylated liposomes and its impact on drug loading by passive equilibration.

Anumita Chaudhury1, Surajit Das, Ronald F S Lee, Kuan-Boone Tan, Wai-Kiong Ng, Reginald B H Tan, Gigi N C Chiu.   

Abstract

The obstacles in translating liposome formulations into marketable products could be attributed to their physical instabilities upon long-term storage as aqueous dispersions. Lyophilization is the most commonly used technique to improve physical stability of liposomes. The development of stable, lyophilized liposomes is focused primarily on the cholesterol-containing liposomes or pure phosphatidylcholine-based liposomes, with minimal studies on cholesterol-free, pegylated (CF-PEG) liposomes which have emerged as an important class of liposome drug carriers. Hence, it is our interest to investigate the effect of lyophilization on CF-PEG liposomes, and specifically, on drug loading via the passive equilibration method. Three different sugar cryoprotectants were used at two different sugar-to-lipid molar ratios (S/L). Our results demonstrated that CF-PEG liposomes lyophilized with sucrose at S/L=5:1 yielded the best cryoprotective effect, as characterized by size, polydispersity indices, and microscopic examination upon liposome reconstitution. The lyophilized liposomes had low water content of 2.59 ± 0.18%. Of note, lyophilized CF-PEG liposomes exhibited two-fold increase in drug content when carboplatin was loaded via the passive equilibration method, and the in vitro drug release profile of these liposomes were not different from that of the non-lyophilized counterparts. Taken together, we envisioned that a stable, lyophilized empty CF-PEG liposome system could be coupled to hydrophilic drug loading via the passive equilibration method to produce a liposomal drug kit product.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22537806     DOI: 10.1016/j.ijpharm.2012.04.036

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

Review 1.  Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies.

Authors:  Hong Wang; Yu Zheng; Qiang Sun; Zhen Zhang; Mengnan Zhao; Cheng Peng; Sanjun Shi
Journal:  J Nanobiotechnology       Date:  2021-10-15       Impact factor: 10.435

2.  A Novel Diosgenin-Based Liposome Delivery System Combined with Doxorubicin for Liver Cancer Therapy.

Authors:  Lixia Chen; Jinshuai Lan; Zhe Li; Ruifeng Zeng; Yu Wang; Lu Zhen; Haojieyin Jin; Yue Ding; Tong Zhang
Journal:  Pharmaceutics       Date:  2022-08-12       Impact factor: 6.525

3.  Resolution Agonist 15-epi-Lipoxin A4 Programs Early Activation of Resolving Phase in Post-Myocardial Infarction Healing.

Authors:  Vasundhara Kain; Fei Liu; Veronika Kozlovskaya; Kevin A Ingle; Subhashini Bolisetty; Anupam Agarwal; Santosh Khedkar; Sumanth D Prabhu; Eugenia Kharlampieva; Ganesh V Halade
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

4.  A quality by design approach for the development of lyophilized liposomes with simvastatin.

Authors:  Alina Porfire; Dana Maria Muntean; Lucia Rus; Bianca Sylvester; Ioan Tomuţă
Journal:  Saudi Pharm J       Date:  2017-02-09       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.